Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter
Company Will Host Conference Call Today at
“With nine quarters now under our belt, we are pleased with the
continued success of EXPAREL in the marketplace, both in new accounts as
well as within existing accounts,” said
Recent Highlights
-
EXPAREL Commercialization: EXPAREL net product sales were
$44.9 million in the second quarter of 2014, compared to$15.2 million in the second quarter of 2013. Pacira also reported 363 new accounts ordering EXPAREL in the second quarter of 2014, averaging 28 new accounts per week. Since launch, 2,815 total accounts have ordered EXPAREL throughJune 30, 2014 , with 469 accounts each ordering more than$100,000 worth of product. -
sNDA Submitted for EXPAREL Nerve Block Indication: In
May 2014 , Pacira announced the submission of a supplemental New Drug Application (sNDA) to theU.S. Food and Drug Administration (FDA ) for a nerve block indication for EXPAREL. The sNDA contains positive data from a Phase 3 study assessing the safety and efficacy of EXPAREL in femoral nerve block for total knee arthroplasty, as well as additional safety data from a Phase 3 study of EXPAREL in intercostal nerve block for thoracotomy. TheFDA has accepted the filing for review and has set a Prescription Drug User Fee Act (PDUFA) action date ofMarch 5, 2015 . -
Data Continues to Support Value of EXPAREL-Based Multimodal Regimen
for Postsurgical Pain Control: Last month, Pacira announced the
published results from the IMPROVE program, a series of open-label,
Phase 4 clinical studies comparing postsurgical narcotic use and
health economic outcomes between patients receiving EXPAREL as the
basis of a multimodal analgesic regimen versus a standard opioid-based
pain management regimen across three surgical procedures—open
colectomy, lap colectomy and ileostomy reversal. Published in the
Journal of Pain Research , the study showed that the EXPAREL group experienced statistically significant reductions in total narcotic consumption, incidence of opioid-related adverse events (ORAEs), total hospital costs and length of hospital stay by 1.4 days.
Second Quarter 2014 Financial Results
-
Total revenues were
$47.2 million , compared to$17.1 million in the second quarter of 2013. -
Total operating expenses were
$50.0 million , compared to$29.2 million in the second quarter of 2013. -
Net loss was
$5.0 million , or$0.14 per share, compared to$14.0 million , or$0.42 per share, in the second quarter of 2013. -
Non-GAAP net income was
$1.5 million , or$0.04 per share, compared to a non-GAAP net loss of$10.8 million , or$0.33 per share, in the second quarter of 2013. -
Pacira ended the second quarter of 2014 with cash and cash
equivalents, restricted cash, short-term investments and long-term
investments (“cash”) of
$179.5 million . InApril 2014 , Pacira raised net proceeds of$110.4 million through the sale of 1.84 million shares of common stock at$64.00 per share in a public offering. - Pacira had approximately 35.5 million weighted average shares of common stock outstanding in the second quarter of 2014.
Today’s Conference Call and Webcast Reminder
The Pacira management team will host a conference call to discuss the
company’s financial results and recent and upcoming developments today,
A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 2791577. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
Non-GAAP Financial Information
This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), non-GAAP net income (loss), because such measures exclude stock-based compensation, loss on early extinguishment of debt and other non-cash charges. These measures supplement our financial results prepared in accordance with GAAP. Pacira management uses these measures to better analyze its financial results and to help make managerial decisions. In management’s opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at Pacira. Such measures should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. Non-GAAP net income (loss) measures are also unlikely to be comparable with non-GAAP disclosures released by other companies. See a reconciliation of non-GAAP net income (loss) to GAAP net loss below.
About Pacira
About EXPAREL®
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about our plans and
expectations regarding EXPAREL, and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” and similar
expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including risks
relating to: the success of our sales and manufacturing efforts in
support of the commercialization of EXPAREL; the rate and degree of
market acceptance of EXPAREL; the size and growth of the potential
markets for EXPAREL and our ability to serve those markets; our plans to
expand the indications of EXPAREL, including for nerve block and the
related timing and success of an sNDA; our plans to evaluate, develop
and pursue additional DepoFoam-based product candidates; clinical
studies in support of an existing or potential DepoFoam-based product;
our plans to continue to manufacture and provide support services for
our commercial partners who have licensed DepoCyt(e); our
commercialization and marketing capabilities; our and Patheon’s ability
to successfully and timely construct dedicated EXPAREL manufacturing
suites; and other factors discussed in the “Risk Factors” of our most
recent Annual Report on Form 10-K for the fiscal year ended
Pacira Pharmaceuticals, Inc. | |||||||
Condensed Consolidated Balance Sheets | |||||||
(unaudited) | |||||||
(in thousands) | |||||||
June 30, | December 31, | ||||||
2014 | 2013 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents, restricted cash and short-term investments | $ | 166,028 | $ | 73,785 | |||
Accounts receivable, net | 20,545 | 14,590 | |||||
Inventories | 19,194 | 15,557 | |||||
Prepaid expenses and other current assets | 3,139 | 2,819 | |||||
Total current assets | 208,906 | 106,751 | |||||
Long-term investments | 13,474 | - | |||||
Fixed assets, net | 53,513 | 48,182 | |||||
Goodwill | 12,520 | 10,328 | |||||
Intangibles, net | 564 | 1,157 | |||||
Other assets | 3,103 | 3,402 | |||||
Total assets | $ | 292,080 | $ | 169,820 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 3,145 | $ | 3,069 | |||
Accrued expenses | 23,035 | 17,885 | |||||
Convertible senior notes (*) | 101,031 | 98,961 | |||||
Current portion of royalty interest obligation | 869 | 1,020 | |||||
Current portion of deferred revenue | 1,426 | 1,008 | |||||
Total current liabilities | 129,506 | 121,943 | |||||
Royalty interest obligation | - | 226 | |||||
Deferred revenue | 10,221 | 3,212 | |||||
Other liabilities | 4,384 | 3,190 | |||||
Total stockholders' equity | 147,969 | 41,249 | |||||
Total liabilities and stockholders' equity | $ | 292,080 | $ | 169,820 | |||
(*) The convertible senior notes are contractually due in 2019. However, because of certain conditions that were met during the three months ended June 30, 2014, the note holders can convert any time during the quarter ended September 30, 2014. |
Pacira Pharmaceuticals, Inc. | ||||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||||
(unaudited) | ||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||
June 30, | June 30, | |||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||
Revenues: | ||||||||||||||||||
Net product sales | $ | 46,034 | $ | 16,278 | $ | 81,776 | $ | 27,113 | ||||||||||
Collaborative licensing and development revenue | 322 | 243 | 574 | 486 | ||||||||||||||
Royalty revenue | 809 | 620 | 1,478 | 1,129 | ||||||||||||||
Total revenues | 47,165 | 17,141 | 83,828 | 28,728 | ||||||||||||||
Operating expenses: | ||||||||||||||||||
Cost of goods sold |
19,954 | 10,214 | 38,081 | 21,605 | ||||||||||||||
Research and development | 5,216 | 4,857 | 10,420 | 10,762 | ||||||||||||||
Selling, general and administrative | 24,837 | 14,080 | 47,426 | 27,017 | ||||||||||||||
Total operating expenses | 50,007 | 29,151 | 95,927 | 59,384 | ||||||||||||||
Loss from operations | (2,842 | ) | (12,010 | ) | (12,099 | ) | (30,656 | ) | ||||||||||
Other (expense) income: | ||||||||||||||||||
Interest income | 61 | 72 | 103 | 145 | ||||||||||||||
Interest expense | (2,079 | ) | (1,914 | ) | (4,185 | ) | (3,433 | ) | ||||||||||
Loss on early extinguishment of debt | - | - | - | (3,398 | ) | |||||||||||||
Royalty interest obligation | (136 | ) | (161 | ) | (256 | ) | (247 | ) | ||||||||||
Other, net | (41 | ) | (18 | ) | (77 | ) | (22 | ) | ||||||||||
Total other expense, net | (2,195 | ) | (2,021 | ) | (4,415 | ) | (6,955 | ) | ||||||||||
Loss before income taxes | (5,037 | ) | (14,031 | ) | (16,514 | ) | (37,611 | ) | ||||||||||
Income tax benefit | - | - | - | 442 | ||||||||||||||
Net loss | $ | (5,037 | ) | $ | (14,031 | ) | $ | (16,514 | ) | $ | (37,169 | ) | ||||||
Net loss per share: | ||||||||||||||||||
Basic and diluted net loss per common share | $ | (0.14 | ) | $ | (0.42 | ) | $ | (0.48 | ) | $ | (1.13 | ) | ||||||
Weighted average common shares outstanding: | ||||||||||||||||||
Basic and diluted | 35,463 | 33,083 | 34,587 | 32,896 |
Pacira Pharmaceuticals, Inc. | ||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Financial Information | ||||||||||||||||||
(unaudited) | ||||||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||
June 30, | June 30, | |||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||
GAAP net loss | $ | (5,037 | ) | $ | (14,031 | ) | $ | (16,514 | ) | $ | (37,169 | ) | ||||||
Non-GAAP adjustments: | ||||||||||||||||||
Stock-based compensation | 5,537 | 2,225 | 9,512 | 4,450 | ||||||||||||||
Loss on early extinguishment of debt | - | - | - | 3,398 | ||||||||||||||
Non-cash debt discount amortization | 1,035 | 1,035 | 2,069 | 1,890 | ||||||||||||||
Total Non-GAAP adjustments | 6,572 | 3,260 | 11,581 | 9,738 | ||||||||||||||
Non-GAAP net income (loss) | $ | 1,535 | $ | (10,771 | ) | $ | (4,933 | ) | $ | (27,431 | ) | |||||||
GAAP basic and diluted net loss per common share | $ | (0.14 | ) | $ | (0.42 | ) | $ | (0.48 | ) | $ | (1.13 | ) | ||||||
Non-GAAP basic net income (loss) per common share | $ | 0.04 | $ | (0.33 | ) | $ | (0.14 | ) | $ | (0.83 | ) | |||||||
Non-GAAP diluted net income (loss) per common share | $ | 0.04 | $ | (0.33 | ) | $ | (0.14 | ) | $ | (0.83 | ) | |||||||
Weighted average common shares outstanding - basic | 35,463 | 33,083 | 34,587 | 32,896 | ||||||||||||||
Weighted average common shares outstanding - diluted | 40,726 | 33,083 | 34,587 | 32,896 |
Source:
Company Contact:
Pacira Pharmaceuticals, Inc.
Jessica
Cho, 973-254-3574
or
Media Contact:
Pure
Communications, Inc.
Susan Heins, 864-286-9597